Please login to the form below

Not currently logged in
Email:
Password:

Dr Thomas Werner joins RIEMSER Pharma advisory board

Former GSK Germany head will support its international expansion
Dr Thomas Werner

German specialty pharmaceuticals company RIEMSER Pharma has appointed Dr Thomas Werner to its advisory board.

The former head of GlaxoSmithKline and Bristol-Myers Squibb Germany will primarily support the company's international expansion strategy.

Dr Kai Deusch, CEO of RIEMSER Pharma, said: "We are very proud to have Dr Thomas Werner on board. His vision and expertise in the pharmaceutical industry will help us to identify new products for our portfolio as part of our growth strategy and open new key markets. The appointment of Thomas Werner represents another step towards establishing RIEMSER Pharma as a leading specialty pharmaceutical company in Europe.”

Dr Werner worked at Bristol-Myers Squibb from 1983 to 1997, ending his time there as managing director for Germany, and then from 1997 to 2009 he served as CEO of GlaxoSmithKline Germany and Central Europe.

Since 2009 he has worked as an independent consultant and a member of the supervisory and advisory boards for a number of pharma companies.

Dr Werner said: "RIEMSER Pharma is an exceptionally promising company, which has already done an excellent job of positioning itself in the dynamic market of specialty pharmaceutical companies. I am looking forward to promoting RIEMSER Pharma's continued growth together with the management team by providing new impetus for strategic product and company acquisitions.”

16th December 2014

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics